Insomnia, A Comorbidity to Take Into Account in the Global Management of Patients With Irritable Bowel Syndrome?
Neurogastroenterology & Motility · 2026-05 · 38 (5)
DOI: 10.1111/nmo.70336 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 05.05.2026. Verfasst von Eline Albert und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, CIC-CRB 1404, CHU Rouen, Rouen, France. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Sleep Initiation and Maintenance Disorders. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaf
Abstract (Originalsprache)
Introduction
In the general population, many people are affected by both insomnia and irritable bowel syndrome (IBS). In this study, we aimed to explore the prevalence of insomnia in patients with IBS and its association with the severity of gastrointestinal and extra‐intestinal symptoms.
Methods
Patients with IBS according to Rome IV criteria, referred to the Physiology Unit of Rouen University Hospital (France) between September 2022 and February 2025, who completed various validated questionnaires during their visit to assess insomnia (Insomnia Severity Index (ISI)), IBS severity (IBS‐SSS), anxiety and depressive symptoms (HAD‐S), quality of life (IBS‐QOL), upper gastrointestinal symptom severity (PAGI‐SYM), and somatic symptom severity (PHQ‐15), were prospectively included in our study. Patients were considered insomniacs when their ISI score was ≥ 15.
Results
Among 700 patients with IBS included in our analysis, 270 (38.6%) were insomniac. The presence of insomnia was associated with more severe gastrointestinal symptoms (IBS severity, IBS‐SSS, p < 0.001) and somatic symptom severity (PHQ‐15, p < 0.001). The hierarchical linear regression analysis showed that the ISI score was associated with higher scores of anxiety and depressive symptoms, the presence of functional dyspepsia and fibromyalgia, and, to a lesser extent, older age and higher IBS severity scores (Adjusted R 2 = 0.265).
Discussion
Our findings suggest that in patients with IBS, insomnia is linked with psychological and somatic symptom burden, and the presence of comorbidities such as functional dyspepsia, but causality cannot be inferred. Future studies using objective sleep assessments, such as polysomnography, are needed to confirm these associations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, CIC-CRB 1404, CHU Rouen, Rouen, France.
- Nantes University, Nantes, France.
- Univ Rouen Normandie, INSERM, Normandie Univ, ADEN UMR1073, Nutrition, Inflammation and Microbiota-Gut-Brain Axis, Rouen, France.
- Department of Gastroenterology and Digestive Oncology, Sorbonne Paris Nord University, Hospital Avicenne, AP-HP, Bobigny, France.
- Department of Physiology, CIC-CRB 1404, CHU Rouen, Rouen, France.
- EMBRACE Lab, Center for Health and Medical Psychology (CHAMP), School of Behavioural Social and Legal Sciences, University of Örebro, Örebro, Sweden.
ORCID-Profile: Eline Albert, Guillaume Gourcerol, Chloé Melchior
Zitieren
APA
Albert, E., Mikhael-Moussa, H., Wuestenberghs, F., Leroi, A. M., Netchitailo, M., Gourcerol, G., Trindade, I. A., Desprez, C., & Melchior, C. (2026). Insomnia, A Comorbidity to Take Into Account in the Global Management of Patients With Irritable Bowel Syndrome?. Neurogastroenterology & Motility, 38(5). https://doi.org/10.1111/nmo.70336
Vancouver
Albert E, Mikhael-Moussa H, Wuestenberghs F, Leroi AM, Netchitailo M, Gourcerol G, et al. Insomnia, A Comorbidity to Take Into Account in the Global Management of Patients With Irritable Bowel Syndrome?. Neurogastroenterology & Motility. 2026;38(5). doi:10.1111/nmo.70336
BibTeX
@article{Albert2026,
author = {Albert, Eline and Mikhael-Moussa, Hiba and Wuestenberghs, Fabien and Leroi, Anne-Marie and Netchitailo, Marie and Gourcerol, Guillaume and Trindade, Inês A and Desprez, Charlotte and Melchior, Chloé},
title = {Insomnia, A Comorbidity to Take Into Account in the Global Management of Patients With Irritable Bowel Syndrome?},
journal = {Neurogastroenterology & Motility},
year = {2026},
volume = {38},
number = {5},
doi = {10.1111/nmo.70336}
}
EUVIMED